Skip to main content
رجوع
NTLA logo

Intellia Therapeutics, Inc.

جودة البيانات: 100%
NTLA
NASDAQ Healthcare Biotechnology
KWD 12.81
▼ KWD 0.30 (-2.29%)
القيمة السوقية: 1.51B
نطاق اليوم
KWD 12.63 KWD 13.18
نطاق 52 أسبوعًا
KWD 5.90 KWD 28.25
حجم التداول
3,336,008
متوسط 50 يوم / 200 يوم
KWD 12.99 / KWD 12.58
الإغلاق السابق
KWD 13.11

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (627 نظير)

المقياس السهم وسيط القطاع
P/E -3.7 0.4
P/B 2.3 2.9
ROE % -53.5 3.7
Net Margin % -609.9 3.9
Rev Growth 5Y % 19.6 10.0
D/E 0.1 0.2

السعر المستهدف للمحللين

Hold
KWD 19.380 +51.3%
Low: KWD 7.000 High: KWD 48.000
ربحية السهم المستقبلية
-KWD 3.619
الإيرادات المقدّرة
59 M

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2030 KWD 8.763
-KWD 1.786 – KWD 99.210
2.5 B 5
FY2029 KWD 3.862
-KWD 0.787 – KWD 43.722
1.6 B 10
FY2028 -KWD 0.688
-KWD 3.570 – KWD 15.817
670 M 12

النقاط الرئيسية

Revenue grew 19.62% annually over 5 years — strong growth
Debt/Equity of 0.14 — conservative balance sheet
Negative free cash flow of -354.66M
PEG of 0.09 suggests growth is underpriced
Capital efficient — spends only 8.54% of revenue on capex

النمو

Revenue Growth (5Y)
19.62%
Revenue (1Y)16.92%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
-53.48%
ROIC-43.25%
Net Margin-609.85%
Op. Margin-651.67%

الأمان

Debt / Equity
0.14
Current Ratio5.08
Interest Coverage0.00

التقييم

P/E Ratio
-3.67
P/B Ratio2.25
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 16.92% Revenue Growth (3Y) 36.58%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 19.62% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 67.67M Net Income (TTM) -412.69M
ROE -53.48% ROA -49.01%
Gross Margin 76.47% Operating Margin -651.67%
Net Margin -609.85% Free Cash Flow (TTM) -354.66M
ROIC -43.25% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.14 Current Ratio 5.08
Interest Coverage 0.00 Dividend Yield 0.00%
Valuation
P/E Ratio -3.67 P/B Ratio 2.25
P/S Ratio 22.36 PEG Ratio 0.09
EV/EBITDA N/A Dividend Yield 0.00%
Market Cap 1.51B Enterprise Value 1.45B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 67.67M 57.88M 36.28M 52.12M 33.05M
Net Income -412.69M -519.02M -481.19M -474.19M -267.89M
EPS (Diluted) -3.81 -5.25 -5.42 -6.16 -3.78
Gross Profit 51.75M 47.59M 27.30M 44.55M 26.16M
Operating Income -440.99M -534.26M -515.29M -458.16M -267.85M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 842.13M 1.19B 1.30B 1.52B 1.29B
Total Liabilities 170.73M 319.06M 250.81M 284.53M 254.22M
Shareholders' Equity 671.39M 871.96M 1.05B 1.24B 1.04B
Total Debt 93.33M 210.20M 115.35M 130.70M 74.02M
Cash & Equivalents 155.46M 189.18M 226.75M 523.51M 123.41M
Current Assets 527.71M 639.86M 998.33M 1.22B 769.30M
Current Liabilities 103.88M 110.85M 115.21M 126.55M 125.83M